Background: Medications used in the treatment of dermatologic conditions have been associated with squamous cell carcinoma (SCC), basal cell carcinoma (BCC), melanoma, and Merkel cell carcinoma (MCC). Objective: The objective of the study was to examine the relationship between systemic dermatologic medications and skin cancer in the FDA Adverse Event Reporting System (FAERS). Methods: Case-control analyses were performed in FAERS from 1968 to 2021 to examine the reporting odds ratios (RORs) for SCC, BCC, melanoma, and MCC. Results: The oral immunosuppressants were all associated with increased ROR of SCC, BCC, melanoma, and MCC. Azathioprine had the highest ROR for SCC (34.13, 95% CI 29.07–40.08), BCC (21.15, 95% CI 20.63–25.98), and MCC (44.76, 95% CI 31.52–63.55), while quinacrine and guselkumab had the highest ROR for melanoma (13.14, 95% CI 1.84–93.89 vs. 12.73, 95% CI 10.60–15.30, respectively). The TNF-α inhibitors were associated with an increased ROR for all skin cancers investigated. Conclusions: The oral immunosuppressants and many biologic medications were associated with an increased ROR of skin cancers including TNF-α inhibitors (etanercept, adalimumab, infliximab), IL-23 or IL-12/23 inhibitors (ustekinumab, risankizumab), and the CD-20 inhibitor rituximab but not dupilumab or IL-17 inhibitors.

Jensen P, Hansen S, Moller B, Leivestad T, Pfeffer P, Geiran O, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999 Feb;40(2 Pt 1):177–86.
Kubica AW, Brewer JD. Melanoma in immunosuppressed patients. Mayo Clin Proc. 2012 Oct;87(10):991–1003.
Ma JE, Brewer JD. Merkel cell carcinoma in immunosuppressed patients. Cancers. 2014 Jun 27;6(3):1328–50.
Harwood CA, Toland AE, Proby CM, Euvrard S, Hofbauer GFL, Tommasino M, et al. The pathogenesis of cutaneous squamous cell carcinoma in organ transplant recipients. Br J Dermatol. 2017 Nov;177(5):1217–24.
Howard MD, Su JC, Chong AH. Skin cancer following solid organ transplantation: a review of risk factors and models of care. Am J Clin Dermatol. 2018 Aug;19(4):585–97.
Wang JL, Yin WJ, Zhou LY, Zhou G, Liu K, Hu C, et al. Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis. Clin Rheumatol. 2020 Mar;39(3):769–78.
Greif CS, Srivastava D, Nijhawan RI. Janus kinase inhibitors and non-melanoma skin cancer. Curr Treat Options Oncol. 2021 Jan 9;22(2):11.
US Food and Drug Administration. FDA Adverse Event Reporting System Public Dashboard. FDA; 2022.
MedDRA Maintenance and Support Services Organization. Medical Dictionary for Regulatory Activities: MedDRA v23.0. Medical Dictionary for Regulatory Activities; 2022.
Faillie JL. Case-non-case studies: principle, methods, bias and interpretation. Therapie. 2019 Apr;74(2):225–32.
Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001 Nov 1;125(1–2):279–84.
Clancy CJ, Nguyen MH. Long-term voriconazole and skin cancer: is there cause for concern?Curr Infect Dis Rep. 2011 Dec;13(6):536–43.
LE Blay P, Mouterde G, Barnetche T, Morel J, Combe B. Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized controlled trials. J Rheumatol. 2012 Apr;39(4):712–5.
Liu R, Wan Q, Zhao R, Xiao H, Cen Y, Xu X. Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis. Cancer Cell Int. 2021 Nov 22;21(1):614.
Cardwell L, Sullivan B, Baran E, Oussedik E, Feldman SR. TNF inhibitors for psoriasis and psoriatic arthritis. Curr Derm Rep. 2017;6(2):113–20.
Zhou L, Wang Y, Wan Q, Wu F, Barbon J, Dunstan R, et al. A non-clinical comparative study of IL-23 antibodies in psoriasis. MAbs. 2021 Jan-Dec;13(1):1964420.
O’Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science. 2005 Sep 16;309(5742):1871–4.
Johnson NM, Prickett KA, Phillips MA. Systemic medications linked to an increased risk for skin malignancy. Cutis. 2019 Oct;104(4):E32–6.
Gu YH, Du JX, Ma ML. Sirolimus and non-melanoma skin cancer prevention after kidney transplantation: a meta-analysis. Asian Pac J Cancer Prev. 2012;13(9):4335–9.
Murray SL, Daly FE, O’Kelly P, O’Leary E, Deady S, O’Neill JP, et al. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients. Ren Fail. 2020 Nov;42(1):607–12.
van Lumig PP, Menting SP, van den Reek JM, Spuls PI, van Riel PL, van de Kerkhof PC, et al. An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors. J Eur Acad Dermatol Venereol. 2015 Apr;29(4):752–60.
Fiorentino D, Ho V, Lebwohl MG, Leite L, Hopkins L, Galindo C, et al. Risk of malignancy with systemic psoriasis treatment in the psoriasis longitudinal assessment registry. J Am Acad Dermatol. 2017 Nov;77(5):845–54.e5.
You do not currently have access to this content.